WuXi Biologics Secures TCE Research Deal with Vertex
Event summary
- WuXi Biologics and Vertex Pharmaceuticals have signed a license and research service agreement for a trispecific T-cell Engager (TCE) targeting B-cell mediated autoimmune diseases.
- Vertex holds exclusive global rights to develop and commercialize the TCE at the preclinical stage.
- WuXi Biologics will receive an upfront payment and potential milestone and royalty payments.
- The agreement includes WuXi Biologics providing contract research and development services for next-generation TCEs.
- As of December 31, 2025, WuXi Biologics was supporting 945 integrated client projects.
The big picture
This agreement underscores the growing trend of pharmaceutical companies leveraging specialized CRDMOs like WuXi Biologics to accelerate drug discovery and development, particularly in complex modalities like T-cell engagers. The deal validates WuXi’s CRDMO model and positions it as a key partner for companies seeking to expand their therapeutic portfolios. The TCE market represents a significant opportunity for both companies, with potential applications across a range of autoimmune diseases.
What we're watching
- Financial Impact
- The size and timing of milestone payments will be key indicators of Vertex’s confidence in the TCE program and WuXi Biologics’ ability to deliver.
- CRDMO Expansion
- WuXi Biologics’ continued reliance on contract research and development services highlights the trend of pharmaceutical companies outsourcing early-stage development, and the potential for further expansion of WuXi's service offerings.
- Pipeline Diversification
- Vertex’s investment in TCEs signals a strategic move to diversify its pipeline beyond its core cystic fibrosis franchise, and the success of this collaboration will influence future outsourcing decisions.
Related topics